[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573194":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":42,"locations":48,"responsibleParty":140,"collaborators":142,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":26,"eligibilityCriteria":158,"healthyVolunteers":154,"sex":159,"minAge":160,"maxAge":26,"enrollmentInfo":161,"targetDuration":26,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":26,"overallStatus":173,"whyStopped":26,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Hemanext","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A (Hypoxic RBCs)","EXPERIMENTAL","Transfusion of hypoxic red blood cells manufactured with Hemanext ONE system",[13],"Device: Hemanext ONE System",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment B (Conventional RBCs)","ACTIVE_COMPARATOR","Transfusion of conventional red blood cells",[19],"Device: Conventional RBCs",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Hemanext ONE System","Hypoxic red blood cells",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Conventional RBCs","Conventional red blood cells",[15],[32,36,39],{"name":33,"affiliation":34,"role":35},"Enrico Novelli, MD, MS","University of Pittsburgh Medical Center","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":38,"role":35},"Biree Andemariam, MD","New England Sickle Cell Institute, University of Connecticut",{"name":40,"affiliation":41,"role":35},"Laurel Omert, MD, FACS","Hemanext Inc.",[43],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Jill Bagdasarian","CONTACT","(781) 301-7474","jill.bagdasarian@hemanext.com",[49,66,82,98,114,130],{"facility":38,"status":26,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Farmington","Connecticut","06030","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-72.83204,41.71982,{"lat":59,"lon":58},[62,65],{"name":37,"role":45,"phone":63,"phoneExt":26,"email":64},"860-679-2100","andemariam@uchc.edu",{"name":37,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":67,"status":26,"city":68,"state":69,"zip":70,"country":53,"countryCode":54,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Johns Hopkins All Children's Hospital","St. Petersburg","Florida","33701",{"type":56,"coordinates":72},[73,74],-82.67927,27.77086,{"lat":74,"lon":73},[77,81],{"name":78,"role":45,"phone":79,"phoneExt":26,"email":80},"Cassandra Josephson, MD","727-767-8884","cjosep22@jhmi.edu",{"name":78,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":83,"status":26,"city":84,"state":85,"zip":86,"country":53,"countryCode":54,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Emory University School of Medicine","Atlanta","Georgia","30322",{"type":56,"coordinates":88},[89,90],-84.38798,33.749,{"lat":90,"lon":89},[93,97],{"name":94,"role":45,"phone":95,"phoneExt":26,"email":96},"Ross Fasano, MD","404-727-5910","ross.fasano@emory.edu",{"name":94,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":99,"status":26,"city":100,"state":101,"zip":102,"country":53,"countryCode":54,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"John Hopkins University School of Medicine","Baltimore","Maryland","21287",{"type":56,"coordinates":104},[105,106],-76.61219,39.29038,{"lat":106,"lon":105},[109,113],{"name":110,"role":45,"phone":111,"phoneExt":26,"email":112},"Elizabeth Crowe, MD, PhD","443-287-6854","ecrowe3@jhmi.edu",{"name":110,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":115,"status":26,"city":116,"state":117,"zip":118,"country":53,"countryCode":54,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University of Pittsburgh","Pittsburgh","Pennsylvania","15213",{"type":56,"coordinates":120},[121,122],-79.99589,40.44062,{"lat":122,"lon":121},[125,129],{"name":126,"role":45,"phone":127,"phoneExt":26,"email":128},"Alesia Kaplan, MD","412-209-7238","kaplana@upmc.edu",{"name":126,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":34,"status":26,"city":116,"state":117,"zip":131,"country":53,"countryCode":54,"cosmosGeoPoint":132,"geoPoint":134,"contacts":135},"15260",{"type":56,"coordinates":133},[121,122],{"lat":122,"lon":121},[136,139],{"name":33,"role":45,"phone":137,"phoneExt":26,"email":138},"412-624-2591","novellie@upmc.edu",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":141,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[143,146,148,149,150],{"name":144,"class":145},"Emory University","OTHER",{"name":147,"class":145},"University of Connecticut",{"name":34,"class":145},{"name":67,"class":145},{"name":151,"class":145},"Johns Hopkins University","100573194","hypoxic-red-blood-cells-in-sickle-cell-anemia-100573194",false,"NCT06743113","Hypoxic Red Blood Cells in Sickle Cell Anemia","A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia","Inclusion Criteria:\n\n1. Male or female at least 7 years of age;\n2. Are able to provide informed consent, and assent as applicable, to participate in the study;\n3. Diagnosis of Sickle Cell Anemia (SCA) (HbSS, HbSβ0 thalassemia) with participation in a chronic transfusion program and have undergone regular transfusions during at least 6 months prior to Screening;\n4. Have had an average interval of at least 14 days between RBC transfusions over the past 6 months;\n5. If on iron chelation therapy, have been on a stable dose for ≥3 months prior to screening;\n\nExclusion Criteria:\n\n1. Are not exclusively transfused at the site;\n2. Have a diagnosis of HbSC disease, HbSβ+ thalassemia or another SCD variant (excluding HbSS and HbSβ0 thalassemia)\n3. Are routinely transfused with washed, packed RBC units;\n4. Have received hemoglobin inducers (e.g. erythropoietin) in the 30 days prior to Screening;\n5. Are currently being evaluated for gene therapy;\n6. Have any clinically significant pulmonary, cardiovascular, endocrine, hepatic, gastrointestinal, renal, infectious, immunological (including significant allo- or auto-immunization) disease, considered not adequately controlled prior to the study;\n7. Are a female of child-bearing potential who is pregnant or planning to become pregnant in the next 14 months;\n8. Have a history of allo-immunization that cannot be managed by the local blood bank;\n9. Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;\n10. Is a ward of the state, prisoner, or transient","ALL","7 Years",{"count":162,"type":163},48,"ESTIMATED","INTERVENTIONAL",[166],"NA","The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.",[169,170,171,172],"Sickle Cell Anaemia","Sickle Cell Anemia Crisis","Sickle Cell Anemia in Children","Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)","NOT_YET_RECRUITING","2026-01-06",{"date":176,"type":177},"2026-01-07","ACTUAL",{"date":179,"type":163},"2026-03",{"date":181,"type":163},"2028-09",{"name":5,"class":6},6]